Literature DB >> 18685006

Association between hypermutator phenotype, clinical variables, mucoid phenotype, and antimicrobial resistance in Pseudomonas aeruginosa.

David J Waine1, David Honeybourne, E Grace Smith, Joanna L Whitehouse, Chris G Dowson.   

Abstract

The presence of hypermutator Pseudomonas aeruginosa was associated with poorer lung function in patients at the Adult West Midlands CF Unit. Mucoid isolates were more likely to be hypermutators. The presence of resistant mutant subpopulations was associated with hypermutator phenotype but was not good enough to be used as a test for this phenotype.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18685006      PMCID： PMC2566124          DOI： 10.1128/JCM.00357-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  15 in total

1.  The estimation of the bactericidal power of the blood.

Authors:  A A Miles; S S Misra; J O Irwin
Journal:  J Hyg (Lond)       Date:  1938-11

2.  BSAC standardized disc susceptibility testing method (version 5).

Authors:  J M Andrews
Journal:  J Antimicrob Chemother       Date:  2006-07-12       Impact factor: 5.790

3.  The exopolysaccharide alginate protects Pseudomonas aeruginosa biofilm bacteria from IFN-gamma-mediated macrophage killing.

Authors:  Jeff G Leid; Carey J Willson; Mark E Shirtliff; Daniel J Hassett; Matthew R Parsek; Alyssa K Jeffers
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

4.  Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing.

Authors:  J E Foweraker; C R Laughton; D F J Brown; D Bilton
Journal:  J Antimicrob Chemother       Date:  2005-05-09       Impact factor: 5.790

5.  Hypochlorite scavenging by Pseudomonas aeruginosa alginate.

Authors:  D B Learn; E P Brestel; S Seetharama
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

6.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

Authors:  Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

7.  Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections.

Authors:  Antonio Oliver; Bruce R Levin; Carlos Juan; Fernando Baquero; Jesús Blázquez
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

8.  Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation.

Authors:  Oana Ciofu; Bente Riis; Tacjana Pressler; Henrik Enghusen Poulsen; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

9.  Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.

Authors:  M D Maciá; N Borrell; M Segura; C Gómez; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

10.  Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion.

Authors:  Maria D Maciá; Nuria Borrell; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191
View more
  28 in total

1.  Genotypic and phenotypic variation in Pseudomonas aeruginosa reveals signatures of secondary infection and mutator activity in certain cystic fibrosis patients with chronic lung infections.

Authors:  Ashley E Warren; Carla M Boulianne-Larsen; Christine B Chandler; Kami Chiotti; Evgueny Kroll; Scott R Miller; Francois Taddei; Isabelle Sermet-Gaudelus; Agnes Ferroni; Kathleen McInnerney; Michael J Franklin; Frank Rosenzweig
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

2.  Effect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators.

Authors:  Natalia R Morero; Mariela R Monti; Carlos E Argaraña
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia.

Authors:  Vanessa E Rees; Deanna S Deveson Lucas; Carla López-Causapé; Yuling Huang; Tom Kotsimbos; Jürgen B Bulitta; Murray C Rees; Adele Barugahare; Anton Y Peleg; Roger L Nation; Antonio Oliver; John D Boyce; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

5.  Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients.

Authors:  C A Colque; A G Albarracín Orio; S Feliziani; R L Marvig; A R Tobares; H K Johansen; S Molin; A M Smania
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

6.  The Essential Role of Hypermutation in Rapid Adaptation to Antibiotic Stress.

Authors:  Heer H Mehta; Amy G Prater; Kathryn Beabout; Ryan A L Elworth; Mark Karavis; Henry S Gibbons; Yousif Shamoo
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

7.  A Low-Molecular-Weight Alginate Oligosaccharide Disrupts Pseudomonal Microcolony Formation and Enhances Antibiotic Effectiveness.

Authors:  Manon F Pritchard; Lydia C Powell; Alison A Jack; Kate Powell; Konrad Beck; Hannah Florance; Julian Forton; Philip D Rye; Arne Dessen; Katja E Hill; David W Thomas
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

8.  Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.

Authors:  Cornelia B Landersdorfer; Vanessa E Rees; Rajbharan Yadav; Kate E Rogers; Tae Hwan Kim; Phillip J Bergen; Soon-Ee Cheah; John D Boyce; Anton Y Peleg; Antonio Oliver; Beom Soo Shin; Roger L Nation; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

9.  The complex interplay of iron, biofilm formation, and mucoidy affecting antimicrobial resistance of Pseudomonas aeruginosa.

Authors:  Amanda G Oglesby-Sherrouse; Louise Djapgne; Angela T Nguyen; Adriana I Vasil; Michael L Vasil
Journal:  Pathog Dis       Date:  2014-02-10       Impact factor: 3.166

10.  The evolution of bacterial mutation rates under simultaneous selection by interspecific and social parasitism.

Authors:  Siobhán O'Brien; Antonio M M Rodrigues; Angus Buckling
Journal:  Proc Biol Sci       Date:  2013-11-06       Impact factor: 5.349
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.